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Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic
stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of
factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad
factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP)
developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence.
Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after
genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-
damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial–mesenchyme
transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP
factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of,
the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional
loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the
promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced
senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS
can promote, the development of age-related cancer by altering the tissue microenvironment.
Citation: Coppe ´ JP, Patil CK, Rodier F, Sun Y, Mun ˜oz DP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS
and the p53 tumor suppressor. PLoS Biol 6(12): e301. doi:10.1371/journal.pbio.0060301
Introduction
Cancer is a multistep disease in which cells acquire
increasingly malignant phenotypes. These phenotypes are
acquired in part by somatic mutations, which derange normal
controls over cell proliferation (growth), survival, invasion,
and other processes important for malignant tumorigenesis
[1]. In addition, there is increasing evidence that the tissue
microenvironment is an important determinant of whether
and how malignancies develop [2,3]. Normal tissue environ-
ments tend to suppress malignant phenotypes, whereas
abnormal tissue environments such at those caused by
inﬂammation can promote cancer progression.
Cancer development is restrained by a variety of tumor
suppressor genes. Some of these genes permanently arrest the
growth of cells at risk for neoplastic transformation, a process
termed cellular senescence [4–6]. Two tumor suppressor
pathways, controlled by the p53 and p16INK4a/pRB proteins,
regulate senescence responses. Both pathways integrate
multiple aspects of cellular physiology and direct cell fate
towards survival, death, proliferation, or growth arrest,
depending on the context [7,8].
Several lines of evidence indicate that cellular senescence is
a potent tumor-suppressive mechanism [4,9,10]. Many poten-
tially oncogenic stimuli (e.g., dysfunctional telomeres, DNA
damage, and certain oncogenes) induce senescence [6,11].
Moreover, mutations that dampen the p53 or p16INK4a/pRB
pathways confer resistance to senescence and greatly increase
cancer risk [12,13]. Most cancers harbor mutations in one or
both of these pathways [14,15]. Lastly, in mice and humans, a
senescence response to strong mitogenic signals, such as
those delivered by certain oncogenes, prevents premalignant
lesions from progressing to malignant cancers [16–19].
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PLoS BIOLOGYInterestingly, some tumor cells retain the ability to senesce in
response to DNA-damaging chemotherapy or p53 reactiva-
tion; in mice, this response arrests tumor progression [20–22].
Despite support for the idea that senescence is a beneﬁcial
anticancer mechanism, indirect evidence suggests that sen-
escent cells can also be deleterious and might contribute to
age-related pathologies [10,23–25]. The apparent paradox of
contributing to both tumor suppression and aging is
consistent with an evolutionary theory of aging, termed
antagonistic pleiotropy [26]. Organisms generally evolve in
environments that are replete with extrinsic hazards, and so
old individuals tend to be rare in natural populations.
Therefore, there is little selective pressure for tumor
suppressor mechanisms to be effective well into old age;
rather, these mechanisms need to be sufﬁciently effective
only to ensure successful reproduction. Further, tumor
suppressor mechanisms could in principle even be delete-
rious at advanced ages, as predicted by evolutionary
antagonistic pleiotropy. Consistent with this view, senescent
cells increase with age in mammalian tissues [27], and have
been found at sites of age-related pathologies such as
osteoarthritis and atherosclerosis [28–30]. Moreover, in mice,
chronically active p53 both promotes cellular senescence and
accelerates aging phenotypes [31,32].
How might senescent cells be deleterious? Senescent cells
acquire many changes in gene expression, mostly docu-
mented as altered mRNA abundance, including increased
expression of secreted proteins [33–41]. Some of these
secreted proteins act in an autocrine manner to reinforce
the senescence growth arrest [37,38,40,41]. Moreover, cell
culture and mouse xenograft studies suggest that proteins
secreted by senescent cells can promote degenerative or
hyperproliferative changes in neighboring cells [35,39,42,43].
Thus, although the cell-autonomous senescence growth arrest
suppresses cancer, factors secreted by senescent cells might
have deleterious cell-nonautonomous effects that alter the
tissue microenvironment. To date, a comprehensive analysis
of the secretory proﬁle of senescent cells is lacking, as is
knowledge regarding how this proﬁle varies with cell type or
senescence inducer, or how it relates to the tumor suppressor
proteins that control senescence.
To ﬁll these gaps in our knowledge, we modiﬁed antibody
arrays to be quantitative and sensitive over a wide dynamic
range and deﬁned the senescence-associated secretory phe-
notype (SASP). We show that this phenotype is complex,
containing elements associated with inﬂammation and
tumorigenesis, and is induced only by genotoxic stress of
sufﬁcient magnitude to cause senescence. SASPs are ex-
pressed by senescent human ﬁbroblasts and epithelial cells in
culture. Moreover, epithelial tumor cells exposed to DNA-
damaging chemotherapy senesce and express a SASP in vivo.
The arrays allowed us to identify two new malignant
phenotypes promoted by senescent cells (the epithelial–
mesenchyme transition and invasiveness), and the SASP
factors responsible for them (interleukin [IL]-6 and IL-8).
Strikingly, the SASP was markedly ampliﬁed by oncogenic
RAS or loss of p53 function. Our results identify a mechanism
by which p53 acts as a cell-nonautonomous tumor suppressor,
and RAS as a cell-nonautonomous oncogene, and provide a
novel framework for understanding how age-related cancers
might progress.
Results
Senescence-Associated Secretory Phenotypes Expressed
by Human Fibroblasts
To determine whether tissue of origin, donor age, or
genotype affected secretory phenotypes, we ﬁrst studied ﬁve
human ﬁbroblast strains, derived from embryonic lung (WI-
38, IMR-90), neonatal foreskin (BJ, HCA2), or adult breast
(hBF184). We cultured the cells under standard conditions,
and either atmospheric (;20%) O2 or 3% O2, which is more
physiological [44]. We made presenescent (PRE) cultures
(.80% of cells capable of proliferation) quiescent by growing
the cells to conﬂuence in order to compare them to
nondividing senescent (SEN) cultures (,10% proliferative)
(Table S1). We induced senescence by either repeatedly
passaging the cells (REP, replicative exhaustion) or by
exposing them to a relatively high dose (10 Gy) of ionizing
radiation (XRA [X-irradiation]) (see Materials and Methods;
Table S1; and Text S1).
To identify proteins secreted by PRE and SEN cells, we
generated conditioned media (CM) by incubating each
culture in serum-free medium for 24 h. After normalizing
for cell number, we analyzed CM using antibody arrays
designed to detect 120 proteins selected for roles in
intercellular signaling (Table S2). We modiﬁed the detection
protocol (see Materials and Methods and Text S1), thereby
rendering the arrays linear over two to three orders of
magnitude; accurate, as determined by concordance with
enzyme-linked immunosorbent assays (ELISAs) of recombi-
nant proteins; and reliable, as determined by comparing
triplicate samples analyzed separately to pooled samples
(Text S2). We quantiﬁed the signals, normalizing intensities to
controls on the arrays to facilitate interexperiment compar-
isons, and calculated secreted protein levels as log2-fold
changes relative to averages of all samples for each cell strain
(baseline). We used these values for quantitative data analyses
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Author Summary
Cells with damaged DNA are at risk of becoming cancerous tumors.
Although ‘‘cellular senescence’’ can suppress tumor formation from
damaged cells by blocking the cell division that underlies cancer
growth, it has also been implicated in promoting cancer and other
age-related diseases. To understand how this might happen, we
measured proteins that senescent human cells secrete into their
local environment and found many factors associated with
inflammation and cancer development. Different types of cells
secrete a common set of proteins when they senesce. This
senescence-associated secretory phenotype (SASP) occurs not only
in cultured cells, but also in vivo in response to DNA-damaging
chemotherapy. Normal cells that acquire a highly active mutant
version of the RAS protein, which is known to contribute to tumor
growth, undergo cellular senescence, and develop a very intense
SASP, with higher levels of proteins secreted. Likewise, the SASP is
more intense when cells lose the functions of the tumor suppressor
p53. Senescent cells promote the growth and aggressiveness of
nearby precancerous or cancer cells, and cells with a more intense
SASP do so more efficiently. Our findings support the idea that
cellular senescence can be both beneficial, in preventing damaged
cells from dividing, and deleterious, by having effects on neighbor-
ing cells; this balance of effects is predicted by an evolutionary
theory of aging.(Datasets S1–S4) and for visual display (Figure 1A). For the
visual display, values over baseline are displayed in grades of
yellow, and values under baseline are displayed in grades of
blue (Figure 1A).
Although the display gives only a semiquantitative assess-
ment of how secretion levels vary (see accompanying scale in
Figure 1A, with log2-fold changes indicated), the data (Data-
sets S1–S4) show that SEN cells secrete signiﬁcantly higher
levels of numerous proteins compared to PRE cells (Figure
1A). We term this phenomenon a senescence-associated
secretory phenotype (SASP). Of 120 proteins interrogated
by the arrays, 41 were signiﬁcantly altered in the SEN CM and
were oversecreted in comparison to PRE CM (Figure 1A and
Dataset S4). However, the SASPs did not result from a general
stimulation of secretion. Seventy-nine proteins showed no
signiﬁcant differences in secreted levels between SEN and
PRE cells, although many of these proteins were easily
detectable by the arrays (Dataset S4).
The SASPs were complex, and their biological effects could
not be predicted a priori. SASP components included
inﬂammatory and immune-modulatory cytokines and chemo-
kines (e.g., IL-6,  7, and  8, MCP-2, and MIP-3a). They also
included growth factors (e.g., GRO, HGF, and IGFBPs), shed
cell surface molecules (e.g., ICAMs, uPAR, and TNF recep-
tors), and survival factors (Figure 1A and Table S2). However,
the SASP was not a ﬁxed phenotype. Rather, it was a wide-
ranging proﬁle because each cell strain also displayed unique
quantitative or qualitative features. In addition, within
Figure 1. SASP of Human Fibroblasts
(A) Soluble factors secreted by the indicated cells were detected by antibody arrays and analyzed as described in the text, Materials and Methods; Text
S2; and Datasets S1–S4. For each cell strain, the PRE and SEN signals were averaged and used as the baseline. Senescence (SEN) was induced by either
repeatedly passaging the cells (REP, replicative exhaustion) or by exposing them to a relatively high dose (10 Gy) of ionizing radiation (XRA, X-
irradiation); for simplification, XRA and REP signals were averaged as a single SEN signal (see also Figure 1C). Signals higher than baseline are displayed
in yellow; signals below baseline are displayed in blue. The numbers on the heat map key (right) indicates log2-fold changes from the baseline.
(B) Validation by immunostaining. PRE WI-38 cells were made senescent by REP or XRA, maintained in 10% serum until fixation, and immunostained for
the cytokines IL-6 and IL-8 and the senescence marker p16INK4a.
(C) Correlation between the SASPs of WI-38 cells induced to senescence by XRA or REP, compared to PRE cells, depicted as log2-fold changes.
(D) WI-38 cells were X-irradiated at the indicated doses. CM was collected 2, 4, 7, or 10 d later, and soluble factors were analyzed by antibody arrays. PRE
cells and cells irradiated with 0.5 Gy transiently arrested growth, but resumed proliferation 24–48 h after CM collection. Cells irradiated with 10 Gy
became senescent, and therefore did proliferate during and beyond the course of the experiment. PRE and SEN (10 d) signals were averaged and used
as the baseline. Signals higher than baseline are displayed in yellow; signals below baseline are displayed in blue.
(E) PRE and SEN cells were analyzed for the indicated mRNAs by quantitative RT-PCR, and normalized to the corresponding PRE values (baselines). The
senescence inducers (REP or XRA) are given in parentheses. Signals higher than baselines are shown in red, signals below baselines are displayed in
green, and the fold changes in signals are given to the right of the heat map. The results are averages for four cell strains (WI-38, IMR90, HCA-2, and BJ),
and the total number of samples for each condition are given below the heat map. An asterisk (*) indicates non-SASP factors (see Figure S4).
(F) Correlation between mRNA and secreted protein levels for SASP (red) and non-SASP (blue) factors (see Figure S4). PRE and SEN values were averaged
to create a baseline; all values were expressed as the log2-fold change relative to this baseline; PRE versus baseline and SEN versus baseline are shown.
doi:10.1371/journal.pbio.0060301.g001
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Senescence-Associated Secretory Phenotypestrains, PRE cultures secreted higher levels of some factors in
20% versus 3% O2, and SEN cultures secreted higher levels of
some factors in 3% versus 20% O2. Thus, although human
cells are less sensitive than mouse cells to hyperphysiological
O2 [44], human cells are not unaffected by the ambient O2
level. Nonetheless, the secretory phenotype was highly
conserved (r . 0.75) in human senescent cells cultured in
3% versus 20% O2. By contrast, the ambient O2 level strongly
affects the secretory phenotype of mouse senescent cells (J. P.
Coppe, C. K. Patil, F. Rodier, A. Krtolica, S. Parrinello, et al.,
unpublished data).
We veriﬁed the secretion levels of several SASP proteins by
ELISAs (Figure S1 and Text S1). Further, because secretion
increased greater than 10-fold for some SASP factors, we
could verify up-regulation by intracellular immunostaining.
For example, IL-6 and IL-8 were barely visible in PRE cells but
clearly detectable in SEN cells (Figure 1B, Figure S2, and Text
S1). We performed the immunostaining on cells in 10%
serum, which allowed us to rule out the possibility that the
SASP was a senescence-speciﬁc response to the serum-free
incubation needed to collect CM. Moreover, the SASPs of SEN
cells induced by REP and XRA were highly correlated (r . 0.9;
Figure 1C), indicating that the phenotype was not speciﬁc to
one senescence inducer. The secretory proﬁles of ﬁbroblast
strains from the same tissues (e.g., BJ and HCA2 from
neonatal foreskin; and IMR90 and Wi-38 from fetal lung)
were highly correlated (Datasets S3 and S4). In subsequent
ﬁgures, data from these related cell strains, as well as from
REP and XRA samples from cells of the same type, were
pooled and averaged in order to simplify the display.
Because REP and XRA induce senescence primarily by
causing genomic damage (from telomere shortening and
DNA breaks, respectively), we asked whether the SASP was a
primary DNA damage response. We irradiated cells using
either 0.5 or 10 Gy. As expected, both doses initiated a DNA
damage response, as determined by p53 stabilization and
phosphorylation (see Figure S3 and Text S1). However, cells
that received 0.5 Gy transiently arrested growth for only 24–
48 h before resuming growth, whereas cells that received 10
Gy underwent a permanent senescence growth arrest (Figure
1D). Antibody arrays performed on CM collected between 2
and 10 d after irradiation showed that only 10 Gy induced a
SASP (Figure 1D and Figure S3). Moreover, cells that senesced
owing to DNA damage developed the SASP slowly, requiring
4–7 d after irradiation before expressing a robust SASP.
These ﬁndings indicate the SASP is not a DNA damage
response per se. However, it is induced by DNA damage of
sufﬁcient magnitude to cause senescence, after which it
requires several days to develop.
We also determined that proteins comprising the SASP
were, in general, up-regulated at the level of mRNA
abundance (Figure 1E and 1F, red symbols and line; Figure
S4, and Text S1). However, for detectable proteins that showed
little or no senescence-associated change in secretion, mRNA
levels were a poor predictor of secreted protein levels (Figure
1F, blue symbols and line; and Figure S4). Thus, antibody
arrays provide a more accurate assessment of the senescence-
associated secretory signature than mRNA proﬁling.
SASPs of Human Epithelial Cells
To determine whether the SASP is limited to ﬁbroblasts, we
studied the secretory activity of epithelial cells. Normal
human prostate epithelial cells (PrECs) underwent a classic
senescence growth arrest in response to X-irradiation (see
Table S1). We collected CM from PRE and SEN PrECs, and
analyzed the factors secreted by these cells using antibody
arrays. Normal PrECs expressed a robust SASP upon
senescence (Figure 2A and Datasets S5–S8). Like ﬁbroblasts,
SEN PrECs secreted many factors at signiﬁcantly higher levels
compared to PRE PrECs. To compare the SASPs of normal
human epithelial and stromal cells senesced under similar
conditions, we analyzed factors that showed a signiﬁcant
change (p , 0.05) upon senescence in PrECs or ﬁbroblasts
induced by XRA only (Figure 2A). Using the hypergeometric
distribution, we determined that the SASPs of both normal
cell types overlapped highly signiﬁcantly (p ¼ ;10
 3; see
Materials and Methods). The trend analysis of all 120 factors
on the arrays (Figure 2B) demonstrated that the secretory
proﬁles were correlated (r ¼ 0.53) and also indicated .66%
overlap between normal ﬁbroblasts and normal epithelial
cells. More speciﬁcally, both SASPs included inﬂammatory or
immune factors such as IL-6, IL-8, or MCP-1, growth
modulators such as GRO and IGFBP-2, cell survival regulators
such as OPG or sTNF RI, and shed surface molecules such as
uPAR or ICAM-1 (Figure 2A). Not surprising, there were also
differences between the SASPs of ﬁbroblasts and PrECs. In
contrast to ﬁbroblasts, three factors (Acrp30, BTC, and
IGFBP-6) were signiﬁcantly down-regulated by SEN in PrECs.
Moreover, IL-1a or HGF were SASP factors unique to either
normal epithelial SASP or normal ﬁbroblast SASP, respec-
tively. This result indicates that the SASP is not limited to
normal stromal cells, and that a substantial overlap between
normal senescent cells of different tissue origins exists.
Some tumor cells retain the ability to senesce in response
to DNA damage, including DNA-damaging chemotherapy
[20–22]. We therefore asked whether prostate cancer cells
also developed a SASP. We studied three prostate tumor cell
lines (BPH1 [45], RWPE1 [46], and PC3 [47], which differ in
their degree of malignancy as follows: PC3 . RWPE1 .
BPH1). As with normal epithelial cells (PrECs), we induced
senescence by XRA, and analyzed CM using antibody arrays
(Datasets S5–S8). SEN epithelial cells secreted signiﬁcantly
higher levels of numerous proteins compared to PRE
counterparts (Figure 2C). The SASPs of prostate epithelial
cells showed striking overlap between normal and trans-
formed cells (Figure 2C and Dataset S8), and there was also
striking similarities between the SASP of ﬁbroblasts and all
epithelial cells, transformed and not transformed (Figure 2C,
asterisks indicate common secreted proteins, and Datasets
S5–S8). Twenty-four proteins were shared between the SASPs
of all ﬁbroblasts (Figure 1A) and all epithelial cells (Figure
2C); this overlap was highly signiﬁcant relative to the overlap
predicted from chance (p ¼ ;10
 5; see Materials and
Methods). We conclude that normal ﬁbroblasts and both
normal and transformed epithelial cells can develop SASPs
that signiﬁcantly overlap, displaying many common, but also
some distinct, features.
Chemotherapy-Induced SASPs Occur In Vivo
Many human tumor cells retain the ability to senesce, in
culture and in vivo, in response to DNA-damaging chemo-
therapeutic agents [48,49]. Epithelial cell lines, as well as
normal ﬁbroblasts, underwent senescence in culture in
response to mitoxantrone (MIT) (see Table S1), a top-
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Senescence-Associated Secretory Phenotypeoisomerase 2b inhibitor that causes DNA breaks and is used
to treat prostate cancer [50]. Antibody arrays (Figure 3A and
Datasets S5–S8) and ELISAs for IL-6, IL-8, and GRO-a (Figure
S1) showed that MIT induced a SASP that correlated well (r¼
0.89) with the XRA-induced SASP (Figure 3A).
The ﬁnding that human prostatic tumor cells express a
SASP in response to MIT in culture allowed us to determine
whether MIT induced a SASP in vivo. We laser captured
approximately 1,000 tumor epithelial cells in biopsies from
human prostate cancer patients before MIT chemotherapy
and in tissues removed after chemotherapy and prostatec-
tomy [50]. By microscopic inspection, the captured cells were
devoid of stromal cells and leukocytes. Since mRNA and
secreted protein levels correlated well for signiﬁcantly up-
regulated SASP factors (Figure 1E and 1F and Figure S4), we
used quantitative PCR to quantify mRNAs encoding sen-
escence and proliferation markers and SASP factors.
After chemotherapy, most of the tumors contained
signiﬁcantly higher levels of p16INK4a and p21 mRNAs,
which are typically up-regulated in senescent cells (Figure
3B). They also contained signiﬁcantly lower levels of
proliferation-associated mRNAs encoding cyclin A, MCM-3,
and PCNA (Figure 3B). These results suggest that MIT
induced tumor cells to senesce in vivo. Importantly, most of
the tumors contained signiﬁcantly higher levels of mRNAs
encoding the SASP components IL-6, IL-8, GM-CSF, GRO-a,
IGFBP-2, and IL-1b (Figure 3C). However, the levels of mRNA
encoding IL-2, which is not a SASP component, did not
signiﬁcantly change on average (Figure 3D). These ﬁndings
(summarized in Figure 3E) suggest that the SASP is not
limited to cultured cells, but also occurs when human cells
senesce in vivo.
SASPs Induce Epithelial–Mesenchyme Transitions
and Invasiveness
The epithelial–mesenchymal transition (EMT) confers
invasive and metastatic properties on epithelial cells, and is
an important step in cancer progression that presages the
conversion of carcinomas in situ to potentially fatal invasive
cancers [51,52]. We found that the ﬁbroblast SASP induced a
classic EMT in two nonaggressive human breast cancer cell
lines (T47D and ZR75.1). Secreted factors from SEN, but not
Figure 2. SASP of Human Epithelial Cells
(A) Soluble factors secreted by the indicated normal cell type (epithelial vs. stromal) were detected by antibody arrays and analyzed as described in the
text, Materials and Methods, and Datasets S5–S8. Normal prostate epithelial cells (PrECs) were induced to senesce by 10 Gy irradiation, and CM from the
PRE and SEN cells were analyzed. The SASP of PrECs was compared side by side to the SASP of SEN(XRA) fibroblasts (WI-38, IMR-90, HCA-2, and BJ). The
PRE values for each cell type served as the baseline. Signals higher than baseline are displayed in yellow; signals below baseline are displayed in blue.
The heat map key (right) indicates log2-fold changes from the baseline. p-Values were calculated by the Student t-test, and are given to the right of the
heat map. ns ¼ not significant (p . 0.05) and defines non-SASP factors.
(B) The log2-fold changes for all 120 proteins detected by the antibody arrays were plotted for SEN(XRA) PrECs and SEN(XRA) fibroblasts, relative to their
PRE baseline. Seventy-nine secreted factors (66%) followed the same regulatory trend (in red). The remaining factors were not coregulated (depictedi n
blue).
(C) Soluble factors produced by the indicated normal or transformed prostate epithelial cells were analyzed by antibody arrays and the results displayed
as described for Figure 1A. For each cell strain or cell line, PRE and SEN signals were averaged and used as the baseline. Signals higher than the baseline
are shown in yellow; signals below baseline are displayed in blue. An asterisk (*) indicates SASP factors that are conserved between all fibroblasts
(Figure 1A) and all epithelial cells.
doi:10.1371/journal.pbio.0060301.g002
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Senescence-Associated Secretory PhenotypePRE, ﬁbroblasts caused dose-dependent epithelial cell scat-
tering, a mesenchymal characteristic (Figure 4A). Moreover,
immunostaining showed that PRE CM preserved surface-
associated b-catenin and E-cadherin, and strong cytokeratin
8/18 expression (Figure 4B), and western analysis showed that
PRE CM preserved low expression of vimentin (see below).
These features are epithelial characteristics frequently
retained by nonaggressive cells [51,52]. By contrast, CM from
SEN cells markedly decreased overall and cell surface b-
catenin and E-cadherin and reduced cytokeratin expression
(Figure 4B), consistent with a mesenchymal transition.
Further, SEN CM down-regulated the tight junction protein
claudin-1, leaving the remaining protein localized primarily
to the nucleus (Figure 4B), a hallmark of an EMT and a
feature of metastatic but not primary tumors [53]. Finally,
SEN CM increased vimentin expression (see below), another
mesenchymal marker and hallmark of an EMT [52].
Consistent with a SASP-induced EMT, CM from SEN, but
not PRE, cells stimulated premalignant MCF-10A and
malignant T47D, ZR75.1, CAMA1, and HCC1187 cells to
invade a basement membrane (Figure 4C), as well as MDA-
MB-231 and MDA-MB-453 (data not shown and unpublished
data). The antibody arrays guided us in identifying the highly
secreted SASP components IL-6 and IL-8 as candidates for
this activity [54,55]. Recombinant IL-6 and IL-8 added to PRE
CM stimulated invasion to varying degrees depending on the
epithelial line. Importantly, IL-6 and IL-8 blocking antibodies
reduced the invasion stimulated by SEN CM (Figure 4C),
indicating a substantial contribution from IL-6 and IL-8.
These results support the idea that paracrine activities of the
SASP can promote malignant phenotypes in nearby prema-
lignant or malignant cells, and identify new SASP activities:
the ability to induce an EMT and to invade a basement
membrane.
Oncogenic RAS Induces an Amplified SASP
Certain oncogenes, of which oncogenic RAS is the
prototype [56], induce senescence in part by indirectly
causing DNA damage [57,58]. RAS and related oncogenes
are best known for generating mitogenic signals that promote
cell-autonomous malignant phenotypes, although RAS-trans-
formed cells are also known to secrete speciﬁc factors that
Figure 3. Chemotherapy-Induced SASP in Culture and In Vivo
(A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3).
Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses.
(B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following
prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as
described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared
to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The
average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E).
(B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA).
(C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-a, IGFBP-2, and IL-1b).
(D) Value for an mRNA encoding a non-SASP–associated protein (IL-2).
(E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for
each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are
displayed in green.
doi:10.1371/journal.pbio.0060301.g003
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Senescence-Associated Secretory Phenotypecontribute to tumorigenesis [59–61]. Our ﬁnding that SASPs
can promote malignant phenotypes in nearby cells suggested
that RAS-like oncogenes might also promote malignancy cell-
nonautonomously via a complex SASP. To test this possibil-
ity, we expressed oncogenic RAS in ﬁbroblasts and epithelial
cells using lentiviruses, allowed the cells to senesce (Table S1),
and analyzed CM using antibody arrays.
RAS induced a SASP that had both common and unique
features relative to SASPs induced by REP or XRA (Figure
5A–5E and Datasets S9–S12). The RAS-induced SASP
subsumed a subset of proteins that showed increased
secretion upon REP- or XRA-induced senescence (Figure
5A). To simplify the visual comparison, we averaged the
highly correlated data (Figure 5A and 5C) from cells
originating from the same tissue (WI-38 þ IMR90 from
embryonic lung, and BJ þ HCA-2 from neonatal foreskin),
and from cells induced to senesce by REP or XRA (see
Datasets S9–S12 for details of the averaging, and the raw and
processed data). Overall, there was good correlation between
the SASPs of ﬁbroblasts induced to senesce by RAS, XRA, or
REP (Figure 5C). Correlations between SEN (XRA or REP)
(averaged) and SEN(RAS) were 0.75 for WI-38 and IMR-90
ﬁbroblasts (averaged) and 0.84 for HCA-2 ﬁbroblasts.
A striking feature of the RAS-induced SASP was that all
ﬁbroblasts induced to senesce by RAS secreted multiple
proteins at levels signiﬁcantly and dramatically higher than
other SEN cells. Because the visual display (Figure 5A) is only
semiquantitative, the quantitative nature of the ampliﬁed
SASP is best illustrated by the bar graph (Figure 5D), which
plots the log2-fold increases in factors secreted by SEN(RAS)
cells compared to their SEN (REP or XRA) counterparts (nine
proteins were signiﬁcantly more secreted in SEN(RAS) versus
SEN(REP;XRA) across all ﬁbroblasts). In addition, the RAS-
induced SASPs had unique features because this SASP
included ﬁve proteins that were not secreted at signiﬁcantly
elevated levels by other SEN (REP or XRA) cells (Figure 5E).
We refer to the overall secretory response of cells induced to
s e n e s c eb yR A S ,i n c l u d i n gt h eq u a n t i t a t i v ei n c r e a s ei n
secretion of speciﬁc proteins and the secretion of proteins
not present in REP or XRA SASPs, as the ampliﬁed SASP. We
conﬁrmed the robust SASP induced by RAS by immunostain-
ing (Figure 5B and Figure S2) and ELISAs (Figure S1).
Further, we conﬁrmed that oncogenic RAS induced an
ampliﬁed SASP in prostate epithelial cells (Figure 5F and 5G).
Taken together, these results suggest that oncogenic RAS,
despite inducing a tumor-suppressive senescence arrest,
might promote tumorigenesis in a cell-nonautonomous
manner by inducing an ampliﬁed SASP.
Cell-Nonautonomous Tumor-Suppressive Function of p53
The p53 pathway is important for establishing and
maintaining the senescence growth arrest caused by geno-
Figure 4. Novel SASP Biological Activities and Key Factors
(A) T47D and ZR75.1 cells were incubated for 2 d with CM from PRE fibroblasts, or SEN fibroblasts induced by XRA. The cells were photographed under
phase contrast, or analyzed for cluster size using an automated Cellomix imager and software. Smaller cluster or clump sizes (pixel
2) indicate greater
scattering. The senescence inducer is given in parentheses. Quadruple asterisks (****) indicate p , 0.001. Error bars indicate the standard deviation
around the mean.
(B) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and immunostained for the indicated EMT marker proteins. Induction of the
mesenchymal marker vimentin by SEN (XRA) CM is shown by the western blot in Figure 7A.
(C) Epithelial cell invasion was measured using Boyden chambers containing CM alone or CM plus IL-6 and IL-8 recombinant proteins or IL-6 and IL-8
blocking antibodies, as described in Materials and Methods. After 16–24 h, invasion was scored by counting the number of cells on the underside of the
membrane. Invasion stimulated by PRE CM was given a value of one, and other conditions were normalized to this value. Invasion was significantly
stimulated by recombinant protein and significantly inhibited by antibodies (p , 0.05). Error bars indicate the standard deviation around the mean.
doi:10.1371/journal.pbio.0060301.g004
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senescence providing they express p16 [62]. We therefore
asked whether p53 established or maintained the SASP. To
inactivate p53, we expressed genetic suppressor element 22
(GSE22, also designated GSE), a peptide that prevents p53
tetramerization and causes inactive monomeric p53 to
accumulate (detectable by immunostaining, Figure S2) [63].
We obtained similar results using a short hairpin RNA
(shRNA) that reduces p53 expression by RNA interference.
We induced WI-38 ﬁbroblasts to senesce by REP or XRA and
then inactivated p53. Because WI-38 and IMR90 cells senesce
with high levels of p16INK4a, they do not resume prolifer-
ation when p53 is inactivated [62]. To simplify the visual
comparison of antibody array readouts, we averaged data
Figure 5. Oncogenic RAS Amplifies the SASP
(A) Soluble factors produced by the indicated fibroblasts were analyzed by antibody arrays and displayed as described for Figure 1A, but in this case,
PRE signals were used as the baseline. Therefore, color intensities represent log2-fold changes of SEN CM relative to PRE CM from cells of the same
genotype under the same culture conditions. We pooled and averaged highly correlated data (see Figure 1C) from cells originating from a common
tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin), and from senescence induced by REP or XRA. Details of the data
processing are provided in Datasets S9–S12. The senescence inducer is given in parentheses. Signals higher than baseline are shown in yellow; signals
below baseline are displayed in blue. The numbers on the heat map key (right) indicates log2-fold changes from the baseline.
(B) WI-38 cells induced to senesce by RAS were immunostained for the SASP proteins IL-6 and IL-8, and the senescence marker p16INK4a.
(C) Correlations between SASPs induced by RAS versus REP or XRA in fibroblasts from embryonic lung (WI-38, IMR-90, left) or neonatal foreskin (HCA-2,
right). Correlations for the individual cell strains and senescence inducers are given in the tables below the graphs.
(D) Shown are the log2-fold values for factors that are significantly increased in CM from fibroblasts induced to senesce by RAS compared to fibroblasts
induced to senesce by XRA or REP. Green indicates SEN WI-38 and IMR-90 cells induced to senesce by RAS versus XRA. Red indicates SEN WI-38 and IMR-
90 induced to senesce by RAS versus REP. Gray indicates HCA2 cells induced to senesce by RAS versus XRA. Blue indicates HCA2 cells induced to
senesce by RAS versus REP.
(E) Shown are the log2-fold values for factors that are uniquely and significantly increased in CM from fibroblasts induced to senesce by RAS compared
to PRE CM, but not significantly changed in CM from fibroblasts induced to senesce by XRA or REP. The color code is identical to (D).
(F) Soluble factors from CM produced by the indicated epithelial cells were analyzed by antibody arrays and displayed as described for Figure 1A, using
PRE CM as the baseline. Signals higher than baseline are shown in yellow; signals below baseline are in blue. Asterisks (*) indicate factors conserved
between fibroblasts and epithelial cells.
(G) Correlations between SASPs induced by RAS versus XRA in prostate epithelial cells.
doi:10.1371/journal.pbio.0060301.g005
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Senescence-Associated Secretory Phenotypefrom highly correlated samples, as described for Figure 5 (see
Datasets S13–S16 for details of the averaging, and the raw and
processed data). The SASPs of SEN WI-38 in which p53 was
either wild type or inactivated after senescence were similar
by visual display (Figure 6A, compare row 1 with row 11), and
by the graphical plot of the log2-fold changes that occurred in
speciﬁc factors (Figure 6B, green bars showing variations
obtained using the appropriate p53 wild-type baseline (e.g.,
SEN(REP.GSE) versus SEN(REP) in WI-38) and Datasets S13–
S16). This ﬁnding indicates that p53 is not required to
maintain an established SASP.
To determine whether p53 is needed to initiate a SASP, we
inactivated p53 in PRE WI-38 cells and then induced
senescence by XRA, REP, or RAS (Figure 6A, rows 8–10).
p53 inactivation did not induce a SASP in PRE cells (Figures
6A, rows 5–7, Figures S1 and S2, and Datasets S13–S16). Upon
senescence by either REP, XRA, or RAS, however, p53-
deﬁcient cells not only developed a SASP, but the magnitude
of the SASP was markedly enhanced (Figure 6A, rows 8–10
versus 1–4), similar to the ampliﬁed SASP induced by RAS.
The quantitative effect of p53 deﬁciency on SASPs is best
illustrated by the bar graph, which plots the log2-fold
increases of signiﬁcantly altered factors secreted by cells
made p53 deﬁcient and then induced to senesce, compared to
cells with wild-type p53 and induced to senesce (Figure 6C,
red and grey bars). We conﬁrmed the robust SASP by
immunostaining (Figure 6D and Figure S2) and ELISA (Figure
S1). Together, these ﬁndings indicate that p53 is not required
to initiate the SASP, and further that it restrains development
of an ampliﬁed SASP.
Importantly, the combined loss of p53 and gain of
oncogenic RAS resulted in the most ampliﬁed SASP (Figure
6A, rows 9–10 versus rows 1–4; Figure 6E and 6F, Figure S5A,
and Text S1). In addition, when p53 was inactivated prior to
XRA, the SASP developed much earlier—between 2 and 4 d
after irradiation (Figure 6G and Figures S5B and S5C),
compared to 4–7 d in cells with wild-type p53 (Figure 1D).
Interestingly, cells induced to senesce by RAS also developed
the ampliﬁed SASP earlier—within 2–4 d after irradiation
(Figures 6G, Figures S5B, S5C, and S6, and Text S1). Thus, loss
of the p53 tumor suppressor, or gain of oncogenic RAS, not
only ampliﬁed the SASP, but also accelerated its develop-
ment.
We also inactivated p53 in ﬁbroblasts that senesce with low
p16INK4a levels: HCA2, BJ, and WI-38 expressing a shRNA
(shp16) that reduces p16INK4a expression by RNA interfer-
ence. In these cells, whether the cells were induced to senesce
by REP or XRA, the SASP was also markedly ampliﬁed (Figure
6A, rows 1–4 versus rows 11–14). The quantitative outcome of
p53 loss on established SASPs is best illustrated by the bar
graph, which lists the signiﬁcantly altered factors secreted by
cells made to senesce and then induced to lose p53 function,
compared to cells induced to senesce and keeping a
functional p53 (Figure 6B, blue and pink bars). As reported
[62], p53 inactivation reversed the growth arrest of these cells,
and the reverted cells resumed growth (Figure S6). We refer
to these cells as REV, and the reversal of the growth arrest
veriﬁed the efﬁcacy of the p53 inactivation. These ﬁndings
indicate that, once established, the SASP cannot be sup-
pressed despite reversion of the senescence growth arrest.
Together, the results indicate that p53 activation by
genotoxic stress not only restrains cell proliferation, but also
restrains the SASP.
The SASPs of p53-deﬁcient cells were qualitatively similar
to those of SEN cells with wild-type p53, resulting in tightly
clustered proﬁles (Figure 6F). The main inﬂuence of p53
status was quantitative. As was the case for RAS-induced
senescence, a subset of SASP proteins was secreted at 5- to 30-
fold higher levels after p53 inactivation (Figure 6B, 6C, and
6E, and Datasets S13–S16). However, there were also unique
features of the p53-deﬁcient SASP (Figure 6B and 6C,
bottom). Interestingly, many factors that were further or
uniquely up-regulated by cells made senescent by RAS were
ampliﬁed in a similar fashion in p53-deﬁcient cells (Figures
6B, 6C, 6E, 5D, and 5E).
p53 also restrained the SASP in prostate epithelial cells.
Factors identiﬁed as part of the epithelial SASP (Figure 2A
and 2C) were ampliﬁed in the PC3, BPH1, and RWPE1 cancer
cells, which are p53 deﬁcient, compared to normal PrECs,
which have wild-type p53 (Figure 6H, top cluster). In
addition, p53-deﬁcient epithelial cells that underwent sen-
escence oversecreted most factors that were restrained by p53
in normal ﬁbroblasts (compare Figure 6H, bottom cluster
versus listed factors in Figure 6B and 6C). Taken together,
these ﬁndings indicate that ﬁbroblasts and epithelial cells that
are induced to senesce by genotoxic stress develop a SASP
that is restrained by p53 activity.
Biological Activities of Amplified SASPs
To determine the possible biological consequences of the
ampliﬁed SASPs, we compared the ability of CM from
ﬁbroblasts with unampliﬁed or ampliﬁed SASPs to induce
an EMT and invasiveness in relatively nonaggressive human
cancer cells. CM from cells with an ampliﬁed SASP was
signiﬁcantly more potent than CM from SEN cells with wild-
type p53 at inducing an EMT, as determined by cell scattering
(compare Figure 7A with Figure 4A), immunostaining
(compare Figure 7A with Figure 4B), and robust expression
of vimentin (Figure 7A), an important quantitative marker of
the EMT [52]. These comparisons were made on cells from the
same single experiment. Further, the ampliﬁed SASP was
signiﬁcantly more potent at stimulating cancer cell invasive-
ness (Figure 7B). Senescent cells have been shown to stimulate
the growth of premalignant or malignant epithelial cells
[42,43]. We found the ampliﬁed SASP stimulated this
epithelial cell growth to a signiﬁcantly greater extent than
the unampliﬁed SASP (Figure 7C). These ﬁndings support the
idea that p53 restrains the cell-nonautonomous promalignant
activities of the SASP.
Discussion
We identiﬁed a hallmark of cellular senescence—the
senescence-associated secretory phenotype or SASP—that
confers cell-nonautonomous paracrine functions on cells,
and is markedly exacerbated by gain of oncogenic RAS or loss
of p53 function.
To study the SASP, we modiﬁed a commercially available
antibody array protocol, substituting radioactivity for chem-
iluminescence as a ﬁnal detection method. This modiﬁcation
greatly improved the dynamic range of the arrays, and
rendered them highly quantitative, reliable, and accurate.
Using this modiﬁed array protocol, we were able to study
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(A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data
from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating
from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and
averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16.
The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in
parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53.
Manipulations are indicated in sequence, separated by a greater than symbol (.). The heat map key (right) indicates the log2-fold changes. Signals
higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and
(C) in which each genetically manipulated cell type is compared to its appropriate control baseline.
(B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM
from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA,
after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (‘‘unreverted’’) upon p53
inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-
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compare similarities and differences among individual
donors, cell types, and tissues of origin. Importantly, we
uncovered quantitative differences caused by oncogenic RAS
or loss of p53 function.
The SASP was a general feature of senescent ﬁbroblasts
from different tissues, donors, and donor ages, as well as
prostate epithelial cells, both normal and transformed. There
were distinct quantitative and qualitative differences among
the different cell strains and lines, as expected given their
different genotypes and tissue origins, indicating that the
SASP is not an invariant phenotype. However, the striking
feature of the phenotype was the marked similarities among
the SASPs from diverse donors, cell types, and tissues,
suggesting the existence of a conserved core secretory
program that any cell undergoing senescence would trigger.
Notably, all the SASPs featured high levels of secreted
inﬂammatory cytokines, immune modulators, and growth
factors, suggesting that SASPs might have myriad biological
activities in addition to those we describe here. Many SASP
factors were up-regulated at the level of mRNA abundance,
suggesting that the phenotype may be controlled transcrip-
tionally.
The correspondence between mRNA levels and SASP
factors allowed us to probe human biopsy samples for the
expression of SASP components before and after DNA-
damaging chemotherapy. Our results showed that human
tumor cells very likely undergo senescence in response to
DNA damaging chemotherapy in vivo, as reported for mice
[49]. Moreover, human tumor cells very likely express a SASP
after chemotherapy. We speculate that components of
chemotherapy-induced SASPs, particularly the high levels of
inﬂammatory cytokines, might contribute to the debilitating
effects of DNA-damaging chemotherapy. These SASPs might
also fuel development of secondary cancers by creating a
local tissue environment that is permissive for the growth and
progression of cells that acquire therapy-induced mutations,
and fail to senesce or die.
Senescent human ﬁbroblasts have been shown to stimulate
the proliferation of premalignant and malignant epithelial
cells in culture, and the tumorigenicity of premalignant
epithelial cells in mouse xenografts [35,42,43]. However, the
mechanisms responsible for these stimulatory activities are
incompletely understood. We identiﬁed two new biological
activities of SEN cells mediated by the SASP: the ability to
induce an EMT in relatively nonaggressive carcinoma cells,
and the ability to stimulate their invasion through a basement
membrane. The antibody arrays allowed us to identify two
SASP factors, IL-6 and IL-8, which explained much of these
two biological activities. In addition to stimulating an EMT
and invasiveness, IL-6 and IL-8 promote inﬂammation, as do
other SASP components. Further, senescent cells secreted or
shed cytokine receptors, which could act as decoys and allow
nearby premalignant or malignant cells to avoid immune
surveillance. As they persist in tissues, senescent cells likely
create a proinﬂammatory tissue environment, which is known
to be protumorigenic [3,64]. Taken together, our ﬁndings
support the idea that senescent cells can create a tissue
microenvironment that promotes multiple stages of tumor
evolution.
Recent ﬁndings show that tumors induced to senesce in
mice gradually regress [21,22], owing perhaps to inﬁltration
by cells of the innate immune system [22]. Inﬂammatory
cytokines and chemokines, such as IL-6, IL-8, GRO-a, MCP-1,
or GM-CSF, which are core features of the SASP, might
contribute to this inﬁltration and eventual clearance. Why,
then, are senescent cells found with increasing frequency
during aging and at sites of age-related pathology? Some SEN
cells might be refractory to immune clearance either because
they are intrinsically different or they produce higher levels
of factors that promote immune evasion. Alternatively, aging
or age-related pathologies may dampen immune responses or
increase the rate at which senescent cells are produced.
Whatever the case, there is mounting evidence that senescent
cells increase with age [65–68] and that chronic inﬂammation
is a prominent feature of aging [69]. If the senescence
response is an example of antagonistic pleiotropy, the
senescent microenvironment created by SASPs might con-
tribute to degenerative diseases of aging, such as osteo-
arthritis or atherosclerosis [28–30], in which senescent cells
are found, as well as fuel the development of late-life cancers.
The evolutionary theory of antagonistic pleiotropy pro-
vides an explanation for the apparent dilemma of how the
senescence response, or any biological process, can be both
beneﬁcial and deleterious, depending on the age of the
organism. It is now recognized that aging is a consequence of
the declining force of natural selection with age [26,70]. This
decline is due to the high mortality caused by extrinsic
hazards in natural environments, resulting in the relative
scarcity of older individuals. Thus, natural selection can favor
expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus;
these cells also revert after p53 inactivation.
(C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM
from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells
expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2
(averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline.
(D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker
p16INK4a, and p53, which accumulates in the presence of GSE22.
(E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation
(GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the
arrow)indicate amplified SASPs.
(F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt)
or oncogenic (o) owing to expression of Ha-RAS
v12.
(G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later.
Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see
also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable.
(H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from
p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were
induced to senesce by XRA.
doi:10.1371/journal.pbio.0060301.g006
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Senescence-Associated Secretory Phenotypea trait that contributes to early life ﬁtness (e.g., protection
from cancer), even if that trait is deleterious in older
individuals (e.g., promoting cancer development). We spec-
ulate that both the growth arrest and the secretory phenotype
of senescent cells can be both beneﬁcial and deleterious.
The senescence-associated growth arrest is beneﬁcial
because it arrests the growth of cells at risk for neoplastic
transformation (cell-autonomous tumor suppressor func-
tion). It can be deleterious, however, because an accumu-
lation of nondividing senescent cells can diminish the ability
of renewable tissues to repair or regenerate. Although some
aged tissues contain less than one or only a few percent of
senescent cells [29,66,71], others can accumulate as many as
15% senescent cells [65,72]. Likewise, the senescence-associ-
ated secretory phenotype might have both beneﬁcial and
deleterious effects. The SASP can be beneﬁcial because some
SASP components reinforce the senescent growth arrest by
an autocrine cytokine network [37,38,40,41], thereby contri-
buting to maintenance of the senescence growth arrest. In
addition, many SASP components are predicted to stimulate
tissue repair and regeneration, and act as ‘‘danger signals’’
within the vicinity of tissues or systemically at the organism
level. Thus, cells undergoing senescence may initially signal
tissue damage, and initiate tissue repair via the SASP. Such
effect would be the beneﬁcial cell-nonautonomous function
of cellular senescence. When chronically present, however,
the secretory activity of senescent cells may be deleterious,
disrupting normal tissue structure and function, and even-
tually stimulate age-associated tissue degeneration or pro-
mote malignant phenotypes (e.g., cancer progression, as
described here).
Oncogenic RAS induced a SASP that was more robust than
other senescence inducers, even when p53 function was
intact. Oncogenic RAS is a cell-autonomous driver of cell
proliferation in many cancer cells. In normal cells, however,
oncogenic RAS causes genotoxic stress and senescence
[57,58], inducing a SASP and thereby conferring complex
cell-nonautonomous oncogenic activities. Thus, oncogenes
such as RAS, which are known to activate protumorigenic
paracrine mechanisms during transformation [59–61], might
also exert cell-nonautonomous protumorigenic effects
through nontransformed cells during the process of inducing
senescence (Figure 7D).
How does oncogenic RAS induce a SASP? One possibility is
Figure 7. Biological Activities of the Amplified SASP
(A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins,
and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in
Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence,
separated by ..
(B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C.
Double asterisks (**) indicate p , 0.02. Error bars indicate the standard deviation around the mean.
(C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green
fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p , 0.05. Error bars
indicate the standard deviation around the mean.
(D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient
magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue
microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can
promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-
autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous
effects of suppressing the intensity of the SASP and its deleterious effects.
doi:10.1371/journal.pbio.0060301.g007
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Senescence-Associated Secretory Phenotypethat this activity of RAS is the result of the genotoxic stress
caused by RAS-stimulated hyperproliferation. Alternatively,
oncogenic RAS might induce a SASP more directly by
stimulating the MAP kinase or other signaling pathway.
Whatever the case, many aspects of the SASP induced by RAS
resembled the SASP of p53-deﬁcient cells.
Genotoxic stress sufﬁcient to cause senescence both
activates p53 and stimulates a SASP. Our data indicate a
dual role for p53 (Figure 7D). First, in responding to
genotoxic stress, p53 imposes the senescence growth arrest,
consistent with its role as a cell-autonomous tumor suppres-
sor. Second, p53 restrains the SASP because loss of p53
function, in combination with senescence-causing damage,
greatly ampliﬁes the SASP. p53 might restrain the SASP in
part by rapidly arresting growth after cells experience DNA
damage (unpublished data), thereby preventing the accumu-
lation of further damage that could ensue should cells
attempt to replicate the damaged DNA template. Addition-
ally, p53 optimizes DNA repair, so cells that lack p53 might
accumulate more DNA damage than cells with wild-type p53,
which in turn might result in a more robust (ampliﬁed) SASP.
Thus, the p53 tumor suppressor may act as an early sensor of
oncogenic stress, and ultimately operate as a molecular
catalyst preventing tissue inﬂammation. The strong correla-
tion between DNA damage and development of a SASP
suggests the SASP might be activated by the mammalian DNA
damage response (DDR). Indeed, our preliminary data suggest
that some components of the DDR are important for
establishing and maintaining the SASP (F. Rodier, J-P. Coppe ´,
C. K. Patil, W. A. M. Hoeijmakers, D. P. Mun ˜oz, et al.,
unpublished data). However, the SASP does not develop
immediately after DNA damage and therefore is not a simple
or classic DDR. Rather, the SASP is a slow and persistent
response to severe or irreparable damage of sufﬁcient
magnitude to cause senescence.
The persistence of the SASP might have important bio-
logical consequences. For example, cells that express low
p16
INK4a levels (e.g., SEN(REP) or SEN(XRA) HCA2) senesce in
response to severe damage by activating the p53 pathway;
when p53 is subsequently inactivated in these cells, they
resume proliferation [62], but do not lose the SASP. Moreover,
they eventually amplify the SASP as they acquire additional
damage owing to proliferation in the absence of a functional
checkpoint. Proliferating p53-deﬁcient cells that senesced in
response to genotoxic stress also developed a highly ampliﬁed
secretory phenotype. These cells are at greater risk for
escaping senescence (unpublished data) and would pose a
danger to the tissue, not only by virtue of their proliferation,
but also by virtue of their ampliﬁed SASP. Moreover, human
cells that bypass oncogene-induced senescence [58], as well as
cells in some human premalignant lesions [73,74], show signs
of a persistently activated DDR. It is possible, if not likely, that
these cells also express a SASP and therefore greatly increase
the risk of cancer progression in vivo. By restraining the SASP,
p53 acts as a cell-nonautonomous tumor suppressor, damp-
ening the protumorigenic activities of the SASP. This activity
might explain why a p53-deﬁcient stroma promotes epithelial
cancer progression [75,76]. We therefore propose that, in
addition to its cell-autonomous ability to suppress cancer by
inhibiting cell growth, p53 might further suppress cancer by
restraining development of an inﬂammatory tissue milieu
caused by a SASP.
Our broad, quantitative assessment of factors secreted by
senescent cells revealed a highly complex secretory pheno-
type. We show here that this phenotype can promote cellular
behaviors associated with malignancy, and suggest that cells
that acquire mutations such as those that inactivate p53 and/
or activate RAS functions can be particularly malignant
owing to the paracrine activities of the SASP. It is very likely,
though, that additional consequences of the SASP will be
uncovered as the many SASP components are tested for
speciﬁc activities.
Materials and Methods
Cells. Cells were obtained, cultured, and made quiescent or
senescent as described in Text S1 [42,66].
Antibody arrays. Cultures were washed and incubated in serum-
free Dulbecco’s modiﬁed Eagle medium (DMEM) for 24 h to generate
CM, which was collected and cells counted. CM was ﬁltered (0.2 lm
pore), frozen at  80 8C ,a n da n a l y z e du s i n ga n t i b o d ya r r a y s
(RayBiotech or Chemicon; Human cat #AA1001CH-8; Mouse cat
#AA1003M-8) essentially as per the manufacturer’s instructions.
Brieﬂy, CM was thawed and concentrated 2- to 3-fold at 4 8C( 3
kDa cutoff). Volumes equivalent to 2310
5 cells were diluted to 1.2 ml
with DMEM and mixed with 300 ll of blocking solution. Array
membranes were preincubated with 1.5 ml of blocking solution,
incubated with CM mixture (overnight, 4 8C), washed 53, then
incubated with biotin-conjugated antibody cocktail (1 h 45 min, room
temperature). After ﬁve washes, detection solution containing 0.265
lCi
35S-streptavidin (732 Ci/mmol; 0.1 mCi/ml) in blocking solution
was added (1 h 45 min, room temperature), followed by ﬁve washes.
Radioactivity bound to the ﬁlters was detected and quantiﬁed using a
phosphorimager. Signals were analyzed as described in Text S2.
ELISA, immunoﬂuorescence, and invasion assays. Assays were
performed as described [77,78], using kits and antibodies described in
Text S1.
Recombinant proteins, blocking antibodies, and vectors. Recombi-
nant proteins and blocking antibodies were obtained as described in
Text S1. Vectors to express oncogenic RAS (Ha-RAS
v12), TIN215C,
and GSE22 were described [62,77,79].
Human study and tissues. Patients with high-risk localized prostate
cancer enrolled and treated on a phase I–II clinical neoadjuvant
chemotherapy trial at the Oregon Health & Science University,
Portland VA Medical Center, Kaiser Permanente Northwest Region,
Legacy Health System, and University of Washington [50]. Patients
provided signed informed consent. From each patient, prostate
biopsies were obtained prior to chemotherapy. At the time of radical
prostatectomy following chemotherapy, cancer-containing tissue
samples were obtained and frozen. Frozen sections were processed
as described in Text S1. Cancerous epithelium from pretreated
biopsy and posttreated prostatectomy specimens were captured
separately and histology of acquired cells veriﬁed by review of
hematoxylin and eosin (H&E)-stained sections from each sample and
review of the laser confocal microscopy (LCM) images.
Real-time polymerase chain reaction (RT-PCR). RNA was isolated
from cultured or laser-captured cells and analyzed as described in
Text S1.
Statistical analyses. Correlation coefﬁcients were evaluated using
Pearson correlation. Statistical signiﬁcance between distributions of
protein or mRNA signals was evaluated using a Student t-test with
two tails, and an assumption of equal variance. For determination of
the signiﬁcance of overlap between epithelial and ﬁbroblast SASPs,
we used the hypergeometric distribution with the following param-
eters: population size¼120 (total proteins on the array), sample size¼
41 (ﬁbroblast SASP; see Figure 1A), successes in population ¼ 39
(epithelial SASP; see Figure 2C), and successes in sample¼24 (overlap
between the ﬁbroblast and epithelial SASPs; see Figure 2C, asterisks).
The same statistical analysis was used to compare SEN(XRA) normal
epithelial cells (PrECs) versus SEN(XRA) normal ﬁbroblasts (the
following parameters were used: 120, 29, 25, and 12; see Figure 2A
and Results).
Supporting Information
Figure S1. ELISA Measurements of SASP Soluble Factors
(A) Selected SASP factors (IL-6 [green], IL-8 [blue), GRO-a/KC
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Senescence-Associated Secretory Phenotype[orange], FGF-7/KGF[(pink], and OPG [grey]) present in CM and
identiﬁed by array analyses were validated and quantiﬁed by ELISAs,
as described in Materials and Methods.
(B) IL-6 (green), IL-8 (blue), and GRO-a (orange) were measured in
CM from SEN(XRA) and SEN(MIT) ﬁbroblasts and epithelial cells by
ELISA. Values were normalized to PRE levels.
Found at doi:10.1371/journal.pbio.0060301.sg001 (196 KB PDF).
Figure S2. Immunostaining for SASP Factors
Selected SASP factors present in CM and detected by array analyses
were visualized intracellularly by immunoﬂuorescence. The cells were
also immunostained for p16 and p53. Each panel is a different ﬁeld.
Cells are designated as described in the text and Table S1. Growth
status indicated by a plus sign (þ) means proliferating, a negative sign
( ) means cell cycle arrested. p53 status indicated by a plus sign (þ)
means wild type, a negative sign ( ) means deﬁcient.
Found at doi:10.1371/journal.pbio.0060301.sg002 (582 KB PDF).
Figure S3. p53 Activation by Low- or High-Dose X-Irradiation
WI-38 cells were X-irradiated with 0, 0.5, or 10 Gy X-rays. Cell lysates
were prepared 2 h or 10 d later and analyzed for total p53 protein
levels, p53 phosphorylated on serine 15 (p-p53ser15), or actin
(loading control) by western blotting.
Found at doi:10.1371/journal.pbio.0060301.sg003 (117 KB PDF).
Figure S4. Comparison between Secreted Protein Levels and mRNA
levels in PRE and SEN(XRA and REP) Human Fibroblasts
(A) Shown are heat maps of selected SASP (secreted protein levels
signiﬁcantly up-regulated by SEN compared to PRE cells) and non-
SASP (secreted protein levels not signiﬁcantly changed by SEN
compared to PRE cells) factors. Studied SASP factors are IL-6 and 8,
GRO-a,- b, and -c, GM-CSF, ICAM-1, OPG, MCP-1,  2, and  4, and
leptin. Studied non-SASP factors are MCP-3, RANTES, ENA-78,
PDGF-B, IGFBP-3, eotaxin, GCP-2, and AREG. The left column lists
the factors, all of which were readily detected by the antibody arrays
(see Dataset S4). The right column gives the correlation between
mRNA and secreted protein levels. For each of the indicated cell
strains (WI-38, IMR-90, HCA-2, and BJ), the colored display shows the
average mRNA level (green below baseline; red above baseline) or
average secreted protein level (blue below baseline; yellow above
baseline), all relative to the average for all samples from each strain.
Some of the SASP components show a high correlation between
mRNA and secreted protein level. However some of the SASP and
almost all of non-SASP factors show a poor or even negative
correlation between the secreted protein and mRNA level.
(B) Overall comparison between secreted protein levels and mRNA
levels in PRE and SEN (XRA and REP). All PRE and SEN measure-
ments were averaged to create a baseline, as described in (A). All data
points presented in (A) are plotted.
(C) PRE and SEN data points are plotted separately. Each plot shows
all SASP and non-SASP factors.
(D) SASP and non-SASP data points are plotted separately. Each plot
shows all PRE and SEN data points.
Found at doi:10.1371/journal.pbio.0060301.sg004 (371 KB PDF).
Figure S5. The SASP Development Is Regulated by p53 and RAS
(A) Comparative analysis of SASPs extent using WI-38 and IMR90 as a
model for senescence establishment and maintenance. The senes-
cence inducer is given in parenthesis. The p53 and RAS status are
listed below (a plus sign [þ] means wild type; a negative sign [ ] means
dysfunctional for p53 and oncogenic for RAS). The secretory proﬁle
extent is the number of signiﬁcantly oversecreted factors composing
each SASP. Using the SEN (REP;XRA) proﬁle as the baseline SASP
proﬁle (p53 and RAS wild type), the other SASPs can be analyzed as
follow: some secreted factors are overall conserved and overlap with
the SEN (REP;XRA) SASP; among these conserved factors, some are
signiﬁcantly further increased; ﬁnally, some other factors are unique
to these other SASPs (see also Figures 5 and 6). This comparison
shows that the loss of p53 tumor suppressor combined with the gain
of oncogenic RAS allow the development of the most ampliﬁed SASP.
(B) WI-38 cells, wild-type (wt), or p53-deﬁcient (expressing GSE;
noted as a minus sign [ ]), were irradiated at the indicated doses or
induced to senescence by RAS (see also Figures 1D and 6G). CM were
collected 2, 4, 7, or 10 d later, and soluble factors were detected and
displayed. PRE and SEN (10 d) signals were averaged and used as the
baseline. Signals higher than baseline are shown in yellow; signals
below baseline are in blue (see Figure 1A and 1D, legend).
(C) Unsupervised hierarchical cluster analysis of cells presented in
Figure 6G. PRE cells secretory proﬁle was compared to the secretory
proﬁle of cells whose CM was collected at 4 d or 10 d after low-dose
(0.5 Gy) or high-dose (10 Gy) irradiation, or induced to senescence
due to oncogenic RAS overexpression, and lacking or not p53
function (GSE). Note that cells that senesced while lacking p53
function or due to oncogenic RAS overexpression cluster together at
each time point after senescence induction. Cells irradiated with 0.5
Gy are very similar to PRE at all time points postdamage (correlation
. 0.95). At 4 d post 10 Gy irradiation, cells harboring a wild-type p53
pathway are still very similar to their PRE counterpart (correlation .
0.95), whereas at 10 d post 10 Gy irradiation, cells are very dissimilar
to PRE (correlation , 0 ; they have developed a SASP). The clustering
analysis also shows that cells that senesced in the absence of p53
function or due to oncogenic RAS overexpression resemble more
each other than cells that senesced with a wild-type p53 background,
suggesting that the loss of p53 and the gain of oncogenic RAS have
similar dominant effects over SASP development and establishment.
Found at doi:10.1371/journal.pbio.0060301.sg005 (142 KB PDF).
Figure S6. Growth Reversion of SEN Cells after p53 Inactivation
SEN(REP) and SEN(XRA) WI-38 cells were monitored for cell growth
for 20 d before infection with lenti-GSE (rectangle). Cell number was
subsequently monitored for an additional 30 d thereafter. Because
SEN WI-38 cells express p16, p53 inactivation by GSE does not revert
the SEN growth arrest. Cells that do not express p16 at SEN (shp16-
expressing WI-38 or unmodiﬁed HCA2 cells) were similarly moni-
tored and infected. In contrast to SEN WI-38 cells, p16-deﬁcient cells
resumed growth (reverted) after p53-inactivation and proliferated for
at least the ensuing 30 d.
Found at doi:10.1371/journal.pbio.0060301.sg006 (79 KB PDF).
Dataset S1. Computational Analysis of Antibody Array Data
Presented in Figure 1 (Human Fibroblasts; SEN(XRA) and SEN(REP)):
Part 1
Found at doi:10.1371/journal.pbio.0060301.sd001 (31 KB DOC).
Dataset S2. Computational Analysis of Antibody Array Data
Presented in Figure 1 (Human Fibroblasts; SEN(XRA) and SEN(REP)):
Part 2
Found at doi:10.1371/journal.pbio.0060301.sd002 (28 KB XLS).
Dataset S3. Computational Analysis of Antibody Array Data
Presented in Figure 1 (Human Fibroblasts; SEN(XRA) and SEN(REP)):
Part 3
Found at doi:10.1371/journal.pbio.0060301.sd003 (142 KB XLS).
Dataset S4. Computational Analysis of Antibody Array Data
Presented in Figure 1 (Human Fibroblasts; SEN(XRA) and SEN(REP)):
Part 4
Found at doi:10.1371/journal.pbio.0060301.sd004 (162 KB XLS).
Dataset S5. Computational Analysis of Antibody Array Data
Presented in Figure 2 and Figure 3 (Human Epithelial Cells;
SEN(XRA)): Part 1
Found at doi:10.1371/journal.pbio.0060301.sd005 (31 KB DOC).
Dataset S6. Computational Analysis of Antibody Array Data
Presented in Figure 2 and Figure 3 (Human Epithelial Cells;
SEN(XRA)): Part 2
Found at doi:10.1371/journal.pbio.0060301.sd006 (39 KB XLS).
Dataset S7. Computational Analysis of Antibody Array Data
Presented in Figure 2 and Figure 3 (Human Epithelial Cells;
SEN(XRA)): Part 3
Found at doi:10.1371/journal.pbio.0060301.sd007 (78 KB XLS).
Dataset S8. Computational Analysis of Antibody Array Data
Presented in Figure 2 and Figure 3 (Human Epithelial Cells;
SEN(XRA)): Part 4
Found at doi:10.1371/journal.pbio.0060301.sd008 (159 KB XLS).
Dataset S9. Computational Analysis of Antibody Array Data
Presented in Figure 5 (Oncogene-Induced Senescence): Part 1
Found at doi:10.1371/journal.pbio.0060301.sd009 (31 KB DOC).
Dataset S10. Computational Analysis of Antibody Array Data
Presented in Figure 5 (Oncogene-Induced Senescence): Part 2
Found at doi:10.1371/journal.pbio.0060301.sd010 (19 KB XLS).
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Senescence-Associated Secretory PhenotypeDataset S11. Computational Analysis of Antibody Array Data
Presented in Figure 5 (Oncogene-Induced Senescence): Part 3
Found at doi:10.1371/journal.pbio.0060301.sd011 (90 KB XLS).
Dataset S12. Computational Analysis of Antibody Array Data
Presented in Figure 5 (Oncogene-Induced Senescence): Part 4
Found at doi:10.1371/journal.pbio.0060301.sd012 (61 KB XLS).
Dataset S13. Computational Analysis of Antibody Array Data
Presented in Figure 6 (p53-Deﬁcient Senescence): Part 1
Found at doi:10.1371/journal.pbio.0060301.sd013 (31 KB DOC).
Dataset S14. Computational Analysis of Antibody Array Data
Presented in Figure 6 (p53-Deﬁcient Senescence): Part 2
Found at doi:10.1371/journal.pbio.0060301.sd014 (25 KB XLS).
Dataset S15. Computational Analysis of Antibody Array Data
Presented in Figure 6 (p53-Deﬁcient Senescence): Part 3
Found at doi:10.1371/journal.pbio.0060301.sd015 (133 KB XLS).
Dataset S16. Computational Analysis of Antibody Array Data
Presented in Figure 6 (p53-Deﬁcient Senescence): Part 4
Found at doi:10.1371/journal.pbio.0060301.sd016 (81 KB XLS).
Table S1. Presenescent and Senescent Cells Characteristics
Labeling index and senescence-associated beta-galactosidase (SA-
bGal) staining of human ﬁbroblasts and human prostate epithelial
cells in vitro.
Found at doi:10.1371/journal.pbio.0060301.st001 (194 KB DOC).
Table S2. Complete Catalog of Entrez Gene IDs for All Proteins
Corresponding to Antibodies on the Arrays
Found at doi:10.1371/journal.pbio.0060301.st002 (61 KB XLS).
Text S1. Supplemental Methods
Found at doi:10.1371/journal.pbio.0060301.sd017 (42 KB DOC).
Text S2. Computational Processing, Analysis, and Validation of
Antibody Arrays
Digitization and quantiﬁcation of antibody arrays; numerical and
statistical methods; linearity; accuracy; and reliability.
Found at doi:10.1371/journal.pbio.0060301.sd018 (289 KB DOC).
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